tbuckley/cabot-search huggingface dataset:
Abstract P014: Oxidative Stress Mediated Regulation of Antioxidants in Cardiac Progenitor Cells
Authors: Gokulakrishnan Iyer, Michael E Davis
Journal: Circulation Research (2011)

Cardiac diseases are the leading causes of death throughout the world and transplantation of endogenous myocardial progenitor population with robust cardiovascular lineage differentiation potential is a promising therapeutic strategy. Therefore, in vitro expansion and transplantation of cardiac progenitor cells (CPCs) is currently in early clinical testing as a potential treatment for severe cardiac dysfunction. However, poor survival and engraftment of cells is one of the major limitations of cell transplantation therapy. Oxidative stress is increased in the ischemic myocardium and indirect inferences suggest the vulnerability of CPCs to oxidative stress. In this study, we show that in vitro, resident c-kit positive CPCs isolated from rat myocardium are significantly (p&lt;0.05) resistant to superoxide-induced apoptosis compared to cardiomyocytes as analyzed by the number of sub-G1 population following xanthine/xanthine oxidase treatment. Interestingly, CPCs have two to four fold higher basal SOD1 and SOD2 activities (p&lt;0.01) compared to cardiomyocytes and endothelial cells. Superoxide treatment increased expression of SOD1 (p&lt;0.01), SOD2 (p&lt;0.01), and glutathione peroxidase (p&lt;0.05) mRNAs within 6 h of treatment compared to control cells. Recent studies suggest the involvement of AKT in controlling cell death, survival and also expression of SOD enzymes. Therefore, we investigated the involvement of AKT in CPCs subjected to oxidative stress. Western blot analysis revealed that the amount of phosphorylated AKT increased significantly within 10 minutes of xanthine/xanthine oxidase treatment. In addition, treatment with LY294002 - a PI3 kinase/AKT inhibitor, increased apoptosis in CPCs treated with superoxide. Our studies demonstrate a novel finding in which resident progenitor cells are protected from oxidative injury by containing higher basal levels of antioxidants as compared to myocytes. Moreover, under oxidant challenge antioxidant levels are regulated, possibly in an AKT-dependent manner. Further elucidation of this pathway may lead to novel therapeutic opportunities.
Response by Hopkins and Holmes to Letter Regarding Article, “Public Health Urgency Created by the Success of Mechanical Thrombectomy Studies in Stroke”
Authors: L. Nelson Hopkins, David R. Holmes
Journal: Circulation (2017)

much of the world, resulting in major public health benefit.We do not advocate for cardiologists to compete with neurointerventionists at major neurovascular centers, but common sense suggests that interested cardiologists should be welcome additions to the stroke team given their wealth of experience in opening occluded arteries.
癌幹様細胞を標的とするヒアルロン酸修飾フラーレンシリカ多機能ナノ粒子併用癌治療【Powered by NICT】
Authors: Wang Hai, Agarwal Pranay, Zhao Shuting, Yu Jianhua, Lu Xiongbin, He Xiaoming
Journal: Biomaterials (2016)
Erratum: An altered responsiveness to thromboxane A2 production mediates an increased Aspirin in PI(A2) platelets (Circulation (October 27, 1998) 98:17 (I1-I1016))
Authors: G. E. Cooke, P. F. Bray, J. D. Hamlington, Y. M. Pham, P. J. Goldschmidt-Clermont
Journal: Circulation (1999)
Abstract 2122: ECG Quantification of Myocardial Scar in Cardiomyopathy Patients with or without Conduction Defects: Correlation with Cardiac Magnetic Resonance and Arrhythmogenesis
Authors: David G Strauss, Ronald H Selvester, João A Lima, Håkan Arheden, Julie M Miller, Gary Gerstenblith, Eduardo Marbán, Robert G Weiss, Gordon F Tomaselli, Galen S Wagner, Katherine C Wu
Journal: Circulation (2008)

Background : Myocardial scarring from infarction (MI) or nonischemic fibrosis forms an arrhythmogenic substrate. The Selvester QRS-score estimates MI size by quantifying changes in Q-, R- and S-wave durations, amplitudes and morphologies from the 12-lead electrocardiogram (ECG). It provides 32 possible points with each point reflecting scarring of 3% of the left ventricle (LV). Although QRS scoring has been extensively validated for estimating MI scar size in the absence of ECG confounders, it has not been validated in patients with left ventricular hypertrophy (LVH), fascicular/bundle branch blocks or nonischemic scar. We assessed the hypotheses that QRS-scores (modified for each conduction type) correctly identify and quantify both ischemic and nonischemic scar as compared to the reference standard of Cardiac Magnetic Resonance - Late Gadolinium Enhancement (CMR-LGE) and QRS-estimated scar size is associated with inducible sustained monomorphic ventricular tachycardia (MVT) during electrophysiologic (EP) testing. Methods and Results: A prospective 162 patient cohort with LV dysfunction (95 ischemic, 67 nonischemic) received 12-lead ECG and CMR-LGE before defibrillator (ICD) implantation for primary prevention of sudden cardiac death. QRS-scores correctly diagnosed CMR-scar presence with receiver operating characteristics (ROC) area under the curve (AUC)=0.91 and correlation for scar quantification of r=0.74, p&lt;0.0001, for all patients. Performance within the LVH, bundle branch/fascicular block and nonischemic subgroups ranged from AUC 0.81– 0.94, r=0.60 – 0.80, p&lt;0.001 for all. Of the 137 patients undergoing EP or device testing, 37/82 (45%) of ischemic and 7/55 (13%) of nonischemic patients had inducible MVT. For each 3 QRS point increase (9% LV scarring), the odds ratio for inducing MVT was 2.2 [95% CI: 1.5–3.2, p&lt;0.001] for all patients; 1.7 [1.0 –2.7, p=0.04)] for ischemics; and 2.2 [1.0 –5.0, p=0.05] for nonischemics. Conclusions : Compared to CMR, QRS-scores identify and quantify MI and nonischemic scar despite ECG confounders. Higher QRS-estimated scar size is associated with increased arrhythmogenic potential and warrants further study as a risk-stratifying tool for patients with left ventricular dysfunction.
Oral contraceptives, breastfeeding and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study
Authors: Cecilia Orellana, Saedis Saevarsdottir, Lars Klareskog, Elizabeth W Karlson, Lars Alfredsson, Camilla Bengtsson
Journal: Annals of the Rheumatic Diseases (2017)

To study whether oral contraceptive (OC) use or breastfeeding (BF) influence the risk of rheumatoid arthritis (RA), stratifying the cases by presence/absence of anticitrullinated protein antibodies (ACPA), and whether these factors interact with known risk factors in the development of ACPA-positive RA.Women aged ≥18 years, participants in the population-based case-control Swedish Epidemiological Investigation of RA study (2641 cases/4251 controls), completed an extensive questionnaire regarding OC, BF and potential confounders. We calculated ORs, with 95% CIs, adjusted for age, residential area, smoking and alcohol consumption. Attributable proportion due to interaction (AP) was estimated to evaluate presence of interaction.Compared with never users, ever and past OC users had a decreased risk of ACPA-positive RA (OR=0.84 (95% CI 0.74 to 0.96); OR=0.83 (95% CI 0.73 to 0.95), respectively). No significant associations were found for ACPA-negative RA. Long duration of OC use (>7 years vs never use) decreased the risk of both ACPA-positive (p=0.0037) and ACPA-negative RA (p=0.0356).A history of long BF decreased the risk only of ACPA-positive RA in a dose-dependent manner (p=0.0086), but this trend did not remain after adjustments. A significant interaction was observed between the lack of OC use and smoking (AP=0.28 (95% CI 0.14-0.42)) on the risk of ACPA-positive RA. No interactions were found for BF.OC decreased the risk of RA, especially ACPA-positive RA, where an interaction with smoking was observed. A long duration of OC use decreased the risk of both disease subsets. We could not confirm an association between BF and a decreased risk of either ACPA-positive or ACPA-negative RA.
P60ペプチドと結合したCD28 2′‐フルオロオリゴヌクレオチドアプタマーによるFoxp3のターゲティング阻害は活動性癌の免疫療法を増強する
Authors: Lozano Teresa, Soldevilla Mario Martinez, Casares Noelia, Villanueva Helena, Bendandi Maurizio, Lasarte Juan Jose, Pastor Fernando
Journal: Biomaterials (2016)
PMAA‐グラフト‐PEGコポリマーに基づく磁気シスプラチンデリバリーナノシステムの構築,特徴およびin vivo評価
Authors: Voulgari Efstathia, Bakandritsos Aristides, Galtsidis Sotiris, Zoumpourlis Vassilis, P Burke Benjamin, S Clemente Goncalo, Cawthorne Christopher, J Archibald Stephen, Tucek Jiri, Zboril Radek, Kantarelou Vasiliki, Karydas Andreas Germanos, Avgoustakis Konstantinos
Journal: Journal of Controlled Release (2016)
Hepatic arterial infusion for unresectable intrahepatic cholangiocarcinoma: An update on survival from two prospective clinical trials.
Authors: Ioannis Konstantinidis, Richard Kinh Gian Do, David H. Gultekin, Mithat Gonen, Lawrence H. Schwartz, Yuman Fong, Peter J. Allen, Michael Ian D'Angelica, Ronald P. DeMatteo, David S. Klimstra, Nancy E. Kemeny, William R. Jarnagin
Journal: Journal of Clinical Oncology (2013)

4116 Background: Patients with unresectable intrahepatic cholangiocarcinoma (IHC) experience poor survival. This study summarizes the long-term outcome of two previously reported clinical trials using hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) (with or without bevacizumab (Bev)) in advanced IHC. Methods: Prospectively collected clinicopathologic and survival data were retrospectively reviewed. Disease response was based on RECIST. All patients underwent pre-treatment dynamic contrast enhanced MRI (DCE-MRI), and tumor perfusion data were correlated with outcome. Results: Forty-four patients were analyzed (FUDR=26, FUDR/Bev=18). At a median follow-up of 30 months, 41 patients had died of disease and 3 were alive. Partial response was observed in 48% of patients, and another 50% had stable disease. Three patients underwent resection after HAI and 84% received additional HAI after removal from the study. Median survival was similar in both trials (FUDR=29 months vs. FUDR/Bev=28.5 months p=0.96). Ten patients (23%) survived ≥3 years including 5 (11%) ≥ 5 years. Tumor perfusion, as measured on pre-treatment DCE-MRI (area under the gadolinium concentration curve (AUC180)), was significantly higher in ≥3-year survivors, and was the only factor that distinguished this group from &lt;3-year survivors (mean AUC180 48.9mM.s vs 32.3mM.s, respectively; p=0.003). Time to liver progression was longer in ≥3-year survivors (19.8 months vs 11.2 months, respectively; p=0.02). Conclusions: HAI chemotherapy can result in prolonged survival in unresectable IHC. Pre-treatment DCE-MRI may predict response and survival. [Table: see text]
Estimated Coronary Flow from Angiographic Images is Correlated with Myocardial Fractional Reserve Measured Using Pressure Wire
Authors: Hikita Hiroyuki, Hayasaka Kazuto, Nakamura Shun, Yamakami Yosuke, Nakagama Shun, Misawa Toru, Mizusawa Masafumi, Kojima Keisuke, Sagawa Yuichirou, Hishikari Keiichi, Yamao Kazuya, Nakashima Emiko, Nakajima Jun, Tanaka Yasuaki, Ohkubo Kenji, Kimura Shigeki, Takagi Katsumasa, Kuwahara Taishi, Takahashi Atsushi, Isobe Mitsuaki
Journal: Circulation (2016)
Induction of Adenocarinoma of the Pyloric Stomach in Mice by Methylcholanthrene [Preliminary Report]
Authors: Stewart, Harold L., Lorenz, Egon
Journal: JNCI Journal of the National Cancer Institute (1941)

Journal Article Induction of Adenocarinoma of the Pyloric Stomach in Mice by Methylcholanthrene [Preliminary Report] Get access Harold L. Stewart, Harold L. Stewart senior pathologist Search for other works by this author on: Oxford Academic PubMed Google Scholar Egon Lorenz Egon Lorenz senior physicist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 2, October 1941, Pages 193–196, https://doi.org/10.1093/jnci/2.2.193 Published: 01 October 1941
PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity—Reply
Authors: Michael J. Koren, Marc S. Sabatine
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Abstract 10245: Arterial Stiffness, Central Pulsatile Hemodynamic Load and Orthostatic Hypotension: A Cross-sectional Survey of Community Residents in Chengdu
Authors: Kai Liu, Xiaoping Chen, Si Wang, Shixi Wan, Yufei Zhou, Pei Pan, Bo Wen, Xin Zhang, Hang Liao, Di Shi, Rufeng Shi
Journal: Circulation (2015)

Introduction: Orthostatic hypotension (OH) is an independent risk factor for cardiovascular morbidity and often unrecognized in the elderly. The association between measures of central pulsatile hemodynamic load or arterial stiffness with OH is unclear. This study evaluated the usefulness of these indexes to identify OH. Hypothesis: We hypothesize that direct measures of central pulsatile hemodynamic load (e.g. central systolic blood pressure) and arterial stiffness (pulse wave velocity) both associated with OH. And Measures of central pulsatile hemodynamic load may represent a better indicator of OH. Methods: A sample of 1099 participants was recruited from the general population who attended health check-ups. Questionnaire, physical examination and laboratory tests were performance by a standard protocol. To assess the correlation between central hemodynamic indexes and the probability of OH, multiple logistic regression analysis was used to estimate the odds ratio in different models, and the discriminatory power of hemodynamic indexes for OH was assessed by the area under the receiver operating curve (ROC). Results: The prevalence of OH in this population was 5.6 %. Compared with those without OH, OH subjects had a higher age, SBP in sitting position, BP in supine position, brachial-ankle PWV (BaPWV) and central systolic blood pressure (CSBP) (all P&lt;0.05). After adjusting for potential confounders, both CSBP (OR=1.039, 95%CI: 1.016-1.062, P=0.001) and BaPWV (OR=1.259, 95%CI: 1.130-1.402, P&lt; 0.001) were significantly positive correlated with OH. However, in subgroup analysis, CSBP (OR=1.017, 95%CI: 0.985-1.050, P=0.310) was insignificantly associated with OH in non hypertension subgroup. In addition, BaPWV seemed to be a better discriminatory power than CSBP in both two subgroups (BaPWVAUC-CSBPAUC =0.127, 95%CI: 0.020-0.233, P=0.02 in non hypertension group; BaPWVAUC-CSBPAUC =0.118, 95%CI: -0.030-0.267, P=0.117 in hypertension group). Conclusion: BaPWV appears to be a better indicator of OH in the elderly. If a patient’s BaPWV is greater than 18m/s, Clinicians should better to carry out supine to standing blood pressures measurement in routine clinical practice.
Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers
Authors: Michal Abraham, Yaron Pereg, Baruch Bulvik, Shiri Klein, Inbal Mishalian, Hana Wald, Orly Eizenberg, Katia Beider, Arnon Nagler, Rottem Golan, Abi Vainstein, Arnon Aharon, Eithan Galun, Yoseph Caraco, Reuven Or, Amnon Peled
Journal: Clinical Cancer Research (2017)

Purpose: The potential of the high-affinity CXCR4 antagonist BL-8040 as a monotherapy-mobilizing agent and its derived graft composition and quality were evaluated in a phase I clinical study in healthy volunteers (NCT02073019).Experimental Design: The first part of the study was a randomized, double-blind, placebo-controlled dose escalation phase. The second part of the study was an open-label phase, in which 8 subjects received a single injection of BL-8040 (1 mg/kg) and approximately 4 hours later underwent a standard leukapheresis procedure. The engraftment potential of the purified mobilized CD34+ cells was further evaluated by transplanting the cells into NSG immunodeficient mice.Results: BL-8040 was found safe and well tolerated at all doses tested (0.5-1 mg/kg). The main treatment-related adverse events were mild to moderate. Transient injection site and systemic reactions were mitigated by methylprednisolone, paracetamol, and promethazine pretreatment. In the first part of the study, BL-8040 triggered rapid and substantial mobilization of WBCs and CD34+ cells in all tested doses. Four hours postdose, the count rose to a mean of 8, 37, 31, and 35 cells/μL (placebo, 0.5, 0.75, and 1 mg/kg, respectively). FACS analysis revealed substantial mobilization of immature dendritic, T, B, and NK cells. In the second part, the mean CD34+ cells/kg collected were 11.6 × 106 cells/kg. The graft composition was rich in immune cells.Conclusions: The current data demonstrate that BL-8040 is a safe and effective monotherapy strategy for the collection of large amounts of CD34+ cells and immune cells in a one-day procedure for allogeneic HSPC transplantation. Clin Cancer Res; 23(22); 6790-801. ©2017 AACR.
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
Authors: Y.K. Shi, L. Wang, B.H. Han, W. Li, P. Yu, Y.P. Liu, C.M. Ding, X. Song, Z.Y. Ma, X.L. Ren, J.F. Feng, H.L. Zhang, G.Y. Chen, X.H. Han, N. Wu, C. Yao, Y. Song, S.C. Zhang, W. Song, X.Q. Liu, S.J. Zhao, Y.C. Lin, X.Q. Ye, K. Li, Y.Q. Shu, L.M. Ding, F.L. Tan, Y. Sun
Journal: Annals of Oncology (2017)
Cutaneous Pseudolymphoma Arising as Wolf’s Post-Herpetic Isotopic Response
Authors: Chase W. Kwon, Diana M. Stephens, Elaine S. Gilmore, Francisco A. Tausk, Glynis A. Scott
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Human prostate vascular dynamics following castration: A study of primary human prostate xenografts.
Authors: Danny R. Gray, Wendy J. Huss, Jeffrey M. Yau, Eric S. Werdin, Gary J. Smith
Journal: Cancer Research (2004)

2382  While the majority of CaP patients treated with hormonal therapy experience clinical regression of disease, essentially all will develop recurrent CaP, suggesting a response of the prostate tissue microenvironment to androgen ablation may have a critical role in facilitating recurrent growth. A previously described model of human angiogenesis in primary xenografts of CaP and benign prostate tissue was used to characterize the response of the human prostate vasculature to castration of the nu/nu mouse host. Human vessels in the xenografts were identified with a combination of human specific antibodies specific for CD31 and CD34. Endothelial cell proliferation or apoptosis was identified using antibodies specific for Ki-67 (proliferation) or activated Caspase-3 (apoptosis). The number of human vessels observed in the prostate xenografts at one month post-transplantation was between 2 or 5 fold greater than the number of vessels in the CaP or benign prostate tissue, respectively, before transplantation. Hosts were castrated at one month post-transplantation, and vascular dynamics were measured over the initial fourteen days post-castration. The number of human vessels identified by CD31/CD34 staining, and the percentage of human vessels containing at least one Ki-67 positive endothelial cell, was initially high, decreased to a low at four days post-castration, and increased markedly by day 14 post-castration. Conversely, the number of vessels that contained at least one activated Caspase-3 positive nucleus was initially low, increased to a peak about day 4, and decreased markedly by day 14. This finding indicates that circulating and/or microenvironmentally available androgens either directly or indirectly modulate prostate vasculature homeostasis. Further, our findings support the hypothesis that hypoxia follows androgen ablation induced vascular involution, and that the hypoxic response may drive an androgen-independent re-vascularization of the prostate in the absence of testicular androgen.